Early onset and long lasting protection in pigs provided by a classical swine fever E2-vaccine candidate produced in the milk of goats

被引:15
作者
Barrera, Maritza [5 ]
Sanchez, Oliberto [1 ,4 ]
Farnos, Omar [4 ]
Rodriguez, Maria P. [4 ]
Dominguez, Patricia [5 ]
Tait, Henry [2 ]
Frias, Maria [5 ]
Avila, Mislay [5 ]
Vega, Ernesto [5 ]
Toledo, Jorge R. [3 ,4 ]
机构
[1] Univ Concepcion, Dept Physiopathol, Fac Biol Sci, Concepcion, Chile
[2] Med Vet Inst, Havana, Cuba
[3] Univ Havana, Dept Plant Biol, Fac Biol, Havana, Cuba
[4] Ctr Genet Engn & Biotechnol CIGB, Anim Biotechnol Dept, Havana, Cuba
[5] Natl Ctr Anim & Plant Hlth CENSA, Havana, Cuba
关键词
CSFV; E2; glycoprotein; Recombinant vaccines; Duration of protection; SUBUNIT MARKER-VACCINE; VIRUS E2 GLYCOPROTEIN; LABORATORY DIAGNOSIS; REPLICON PARTICLES; VIRAL CHALLENGE; STRAIN-C; CSFV; EXPRESSION; ANTIBODIES; RESPONSES;
D O I
10.1016/j.vetimm.2009.06.015
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
For vaccination against classical swine fever virus (CSFV), it is strongly desirable to induce a rapid and long lasting protection. At present, only live attenuated CSFV vaccines have shown early onset of protection, differing with the recombinant subunit-based vaccines reported so far. Recently, a new vaccine formulation based on E2 envelope viral glycoprotein produced in the milk of goats (E2his) has been shown to induce a highly protective response in pigs against CSFV infection. Pigs immunized with a single dose of this vaccine candidate, formulated as a water-in oil emulsion, elicited an effective response against CSF as early as 7 days post-vaccination. No severe CSF clinical signs were observed and no animals died although the challenge dose was 10(5) PDL50 of a highly pathogenic CSFV strain. Noticeably, this response completely prevented CSFV infection in pigs when they were challenged under the same conditions 2 weeks after a single dose of the recombinant E2his vaccine formulation. A schedule consisting of a primary immunization with the same vaccine candidate, followed by a booster dose 2 weeks later induced a highly protective response against CSFV infection for as long as 9 months post-vaccination. These promising results demonstrate by far the feasibility of using the E2his-based vaccine in regional programs for preventing and controlling CSF. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:25 / 32
页数:8
相关论文
共 33 条
[1]  
[Anonymous], 2004, MANUAL DIAGNOSTIC TE, V5th
[2]   Determination of the onset of the herd-immunity induced by the E2 sub-unit vaccine against classical swine fever virus [J].
Bouma, A ;
De Smit, AJ ;
De Jong, MCM ;
De Kluijver, EP ;
Moormann, RJM .
VACCINE, 2000, 18 (14) :1374-1381
[3]   Heterologous gene expression from transmissible gastroenteritis virus replicon particles [J].
Curtis, KM ;
Yount, B ;
Baric, RS .
JOURNAL OF VIROLOGY, 2002, 76 (03) :1422-1434
[4]  
DAHLE J, 1995, BERL MUNCH TIERARZTL, V108, P20
[5]   Origin and evolution of viruses causing classical swine fever in Cuba [J].
de Arce, HD ;
Ganges, L ;
Barrera, M ;
Naranjo, D ;
Sobrino, F ;
Frías, MT ;
Núñez, JI .
VIRUS RESEARCH, 2005, 112 (1-2) :123-131
[6]   Duration of the protection of an E2 subunit marker vaccine against classical swine fever after a single vaccination [J].
de Smit, AJ ;
Bouma, A ;
de Kluijver, EP ;
Terpstra, C ;
Moormann, RJM .
VETERINARY MICROBIOLOGY, 2001, 78 (04) :307-317
[7]   Laboratory diagnosis, epizootiology, and efficacy of marker vaccines in classical swine fever: A review [J].
de Smit, AJ .
VETERINARY QUARTERLY, 2000, 22 (04) :182-188
[8]   An experimental infection with classical swine fever in E2 subunit marker-vaccine vaccinated and in non-vaccinated pigs [J].
Dewulf, J ;
Laevens, H ;
Koenen, F ;
Vanderhallen, H ;
Mintiens, K ;
Deluyker, H ;
de Kruif, A .
VACCINE, 2000, 19 (4-5) :475-482
[9]   Marker vaccine strategies and candidate CSFV marker vaccines [J].
Dong, Xiao-Nan ;
Chen, Ying-Hua .
VACCINE, 2007, 25 (02) :205-230
[10]   A DNA vaccine expressing the E2 protein of classical swine fever virus elicits T cell responses that can prime for rapid antibody production and confer total protection upon viral challenge [J].
Ganges, L ;
Barrera, M ;
Núñez, JI ;
Blanco, I ;
Frias, MT ;
Rodríguez, F ;
Sobrino, F .
VACCINE, 2005, 23 (28) :3741-3752